International Journal of Hypertension / 2012 / Article / Tab 2

Clinical Study

Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension

Table 2

Mean seated clinic trough BP and changes from baseline by treatment group.

T80/H25 ( )V160/H25 ( )Placebo ( )

SBP, mm Hg
 Baseline (SD)167.6 (5.4)168.3 (5.8)167.1 (5.9)
 End of study (SD)136.6 (15.3)139.75 (16.4)160.2 (14.9)
 Change from baseline (SD)−31.1 (15.1)−28.6 (15.9)−7.0 (14.3)
 Adjusteda change from baseline (SE)−31.1 (0.9)−28.4 (0.9)−7.3 (1.7)
 Comparison to T80/H25 (95% CI)−2.7 (−5.1, −0.3)
−23.8 (−27.5, −20.0)
DBP, mm Hg
 Baseline (SD)103.2 (4.4)103.4 (4.8)103.4 (4.1)
 End of study (SD)85.1 (9.4)87.3 (10.4)98.3 (10.1)
 Change from baseline (SD)−18.1 (8.7)−16.1 (9.3)−5.0 (9.5)
 Adjusteda change from baseline (SE)−18.3 (0.52)−16.3 (0.5)−5.3 (1.0)
 Comparison to T80/H25 (95% CI)−2.0 (−3.4, −0.6)
−13.0 (−15.2, −10.8)

BP: blood pressure; CI: confidence interval; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: standard deviation; SE: standard error; T80/H25: telmisartan 80 mg/hydrochlorothiazide 25 mg; V160/H25: valsartan 160 mg/hydrochlorothiazide 25 mg.
aAdjusted for effects of baseline, study, gender, and race.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.